The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5
Abstract
Tumors put in a vulnerable position: Cancer cells often display alterations in metabolism that help fuel their growth. Such metabolic “rewiring” may also work against the cancer cells, however, by creating new vulnerabilities that can be exploited therapeutically. A variety of human tumors show changes in methionine metabolism caused by loss of the gene coding for 5-methylthioadenosine phosphorylase (MTAP). Mavrakis et al. and Kryukov et al. found that the loss of MTAP renders cancer cell lines sensitive to growth inhibition by compounds that suppress the activity of a specific arginine methyltransferase called PRMT5. Conceivably, drugs that inhibit PRMT5 activity could be developed into a tailored therapy for MTAP-deficient tumors. Science , this issue pp. 1208 and 1214
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of MTAP expression can result in another vulnerability for cancer cells because the MTA that accumulates following MTAP loss can act as a potent inhibitor of the enzyme arginine methyltransferase 5 (PRMT5).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mavrakis et al., 2016
In the citing paper
“Deletion of the tumor suppressor CDKN2A results in concomitant deletion of the methionine salvage pathway enzyme methylthioadenosine phosphorylase (MTAP) in many cancers, including 53% of glioblastomas and 26% of pancreatic cancers (Mavrakis et al., 2016).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mavrakis et al., 2016
In the citing paper
“MTAP loss results in reduced PRMT5 activity and renders MTAP-null cancer cell more sensitive to PRMT5 depletion than isogenic counterparts that express MTAP (Kryukov et al., 2016; Marjon et al., 2016; Mavrakis et al., 2016).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mavrakis et al., 2016
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Self-citationHow good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,743
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O. S., Paciorek, W. A., Womack, T. O., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,084
An introduction to data reduction: space-group determination, scaling and intensity statistics
Evans, P. R. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s090744491003982x · Cited by 1,507
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
Kryukov, G. V., Wilson, F. H., Ruth, J. R., Paulk, J., Tsherniak, A., Marlow, S. E., Vazquez, F., Weir, B. A., Fitzgerald, M. E., Tanaka, M., et al. (2016) · Science · doi:10.1126/science.aad5214 · Cited by 688
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
Chan-Penebre, E., Kuplast, K. G., Majer, C. R., Boriack-Sjodin, P. A., Wigle, T. J., Johnston, L. D., Rioux, N., Munchhof, M. J., Jin, L., Jacques, S. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1810 · Cited by 569
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
Qi, W., Chan, H., Teng, L., Li, L., Chuai, S., Zhang, R., Zeng, J., Li, M., Fan, H. X., Lin, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1210371110 · Cited by 557
Self-citation
Cited by
Sorted by citations
Items 601–623 of 623
BindingDB (2022) · UC San Diego · doi:10.7270/q2rr22z5
BindingDB Entry 50010923: Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5).
BindingDB (2021) · UC San Diego · doi:10.7270/q2ft8qk8
BindingDB (2022) · UC San Diego · doi:10.7270/q26977dh
BindingDB (2026) · UC San Diego · doi:10.7270/q21r6wfc
Diluvio, A., Lucà, S., Iavarone, L., Masola, V., Fiorelli, A., Morgillo, F., D’Abbronzo, G., & Franco, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219653
High-throughput evaluation of enzyme inhibitor mode-of-action
Fernández‐Montalván, A. E., Georgi, V., Corrionero, A., Alfonso, P., McWhirter, C. L., Michaud, A., & Robers, M. B. (2026) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2026.10.040
Metadata
- Authors
- Mavrakis, K. J., McDonald, E. R., Schlabach, M. R., Billy, E., Hoffman, G. R., deWeck, A., Ruddy, D. A., Venkatesan, K., Yu, J., McAllister, G., Stump, M., deBeaumont, R., Ho, S., Yue, Y., Liu, Y., Yan-Neale, Y., Yang, G., Lin, F., Yin, H., Gao, H., Kipp, D. R., Zhao, S., McNamara, J. T., Sprague, E. R., Zheng, B., Lin, Y., Cho, Y. S., Gu, J., Crawford, K., Ciccone, D., Vitari, A. C., Lai, A., Capka, V., Hurov, K., Porter, J. A., Tallarico, J., Mickanin, C., Lees, E., Pagliarini, R., Keen, N., Schmelzle, T., Hofmann, F., Stegmeier, F., & Sellers, W. R.
- Affiliations
- Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
- Novartis Institutes for Biomedical Research, Basel CH-4002, Switzerland.
- Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA.
- Novartis (China) (CN)
- Novartis Institutes for BioMedical Research (CH)
- Corresponding author
- Mavrakis, Konstantinos J.
- McDonald, E. Robert
- Schlabach, Michael R.
- Hoffman, Gregory R.
- Schmelzle, Tobias
- Hofmann, Francesco
- Stegmeier, Frank
- Sellers, William R.
- ORCID
- McDonald, E. Robert
- Schlabach, Michael R.
- Ruddy, David A.
- Venkatesan, Kavitha
- Yu, Jianjun
- Ho, Samuel
- Liu, Yue
- Yin, Hong
- Kipp, D. Randal
- Zhao, Songping
- McNamara, Joshua T.
- Sprague, Elizabeth R.
- Lin, Ying
- Cho, Young Shin
- Ciccone, David
- Lai, Albert
- Tallarico, John
- Lees, Emma
- Pagliarini, Raymond
- Keen, Nicholas
- Schmelzle, Tobias
- Stegmeier, Frank
- Sellers, William R.
- Venue
- Science
- Published
- 2016-03-11
- Volume
- 351
- Issue
- 6278
- Pages
- 1208-1213
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2287840388
- Cited by
- 607
- References
- 29
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 72 · 2023: 54 · 2022: 58 · 2021: 48 · 2020: 40 · 2019: 50 · 2018: 39 · 2017: 37 · 2016: 25
- FWCI
- 26.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Office of Science, Office of Basic Energy Sciences, U.S. Department of Energy (DE-AC02-06CH11357)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer-related gene regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- MTAP, CDKN2A, PRMT5, methylthioadenosine, methionine salvage pathway, methionine metabolism, cancer cell lines, PRMT5 inhibition, tumor suppressor loss, cancer metabolism, targeted cancer therapy
- MeSH terms
- Cell Survival, Deoxyadenosines, Humans, Methionine, Neoplasms, Protein-Arginine N-Methyltransferases, Purine-Nucleoside Phosphorylase, Thionucleosides, Gene Deletion, Cyclin-Dependent Kinase Inhibitor p16, RNA, Small Interfering, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
